Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Rhabdomyosarcoma with unknown primary tumor site. A report from European Pediatric Soft Tissue Sarcoma Study Group (EpSSG)
  • +5
  • Maria Carmen Affinita,
  • Johannes Merks,
  • Julia Chisholm,
  • stephanie haouy,
  • Angélique Rome,
  • Marco Rabusin,
  • Bernadette Brennan,
  • Gianni Bisogno
Maria Carmen Affinita
University of Padua

Corresponding Author:[email protected]

Author Profile
Johannes Merks
Utrecht University
Author Profile
Julia Chisholm
Royal Marsden Hospital
Author Profile
stephanie haouy
University Hospital Centre Montpellier
Author Profile
Angélique Rome
APHM
Author Profile
Marco Rabusin
IRCCS Materno Infantile Burlo Garofolo
Author Profile
Bernadette Brennan
Royal Manchester Children's Hospital, Manchester, United Kingdom.
Author Profile
Gianni Bisogno
University of Padua
Author Profile

Abstract

BACKGROUND: Rhabdomyosarcoma (RMS) is an aggressive malignancy, and 20% of children present with metastases at diagnosis. Patients presenting with disseminated disease very occasionally have no clear evidence of a primary tumor mass. Since these patients have rarely been investigated, we report on a series of patients with RMS and unknown primary tumor site registered in the MTS 2008 protocol (October 2008 - December 2016) coordinated by the European pediatric Soft tissue sarcoma Study Group. METHODS: Patients were administered 9 cycles of induction chemotherapy, and 48 weeks of maintenance chemotherapy. Surgery and/or radiotherapy was planned after the first assessment of tumor response, and implemented after six cycles of chemotherapy. If feasible, radiotherapy to all sites of metastasis was recommended. RESULTS: We identified 10 patients with RMS and unknown primary site, most of them adolescents (median age 15.8 years, range 4.6-20.4). Nine had fusion-positive alveolar RMS. Multiple organ involvement was identified in 7 patients, 2 only had bone marrow disease, and 1 only had leptomeningeal dissemination. All patients were given chemotherapy, 4 were irradiated, and none had surgery. Three patients underwent allogeneic bone marrow transplantation. At the time of this analysis, only 2 patients are alive in complete remission: 1 had received radiotherapy; and 1 had a bone marrow transplant. CONCLUSIONS: RMS with unknown primary tumor occurs mainly in adolescents and is typically fusion-positive alveolar. Radiotherapy may be important, but survival is poor and patients should be offered enrollment in investigational trials.
03 May 2022Submission Checks Completed
03 May 2022Assigned to Editor
03 May 2022Submitted to Pediatric Blood & Cancer
06 May 2022Reviewer(s) Assigned
18 May 2022Review(s) Completed, Editorial Evaluation Pending
23 May 2022Editorial Decision: Revise Minor
13 Jul 2022Submission Checks Completed
13 Jul 2022Assigned to Editor
13 Jul 20221st Revision Received
20 Jul 2022Reviewer(s) Assigned
25 Jul 2022Review(s) Completed, Editorial Evaluation Pending
05 Aug 2022Editorial Decision: Accept
12 Sep 2022Published in Pediatric Blood & Cancer. 10.1002/pbc.29967